Dear Editor,CLDN18.2(CLDN),a member of tight junction protein family,is strictly limited to express on differentiated epithelial cells of the gastric mucosa and abnormal overexpression has been found in many cancers,e...Dear Editor,CLDN18.2(CLDN),a member of tight junction protein family,is strictly limited to express on differentiated epithelial cells of the gastric mucosa and abnormal overexpression has been found in many cancers,especially in digestive system malignancies.1 Those features make CLDN a potential therapeutic target.However,monoclonal antibody targeting CLDN induce limited antitumor immune responses in clinical trials and fusion of strong immunomodulators might be needed to enhance its efficacy.High dose IL-2 activates tumor infiltrating lymphocytes(TILs),but the severe toxicity and poor tumor targeting limits its use.展开更多
基金This work was supported by Cancer Prevention and Research Institute of Texas(CPRIT)grant RR150072 given to Y.-X.Fthe NIH/NCI grant R01-CA240952 given to J.Q.National Natural Science Foundation of China 82250710684 to Y.F.The funders had no role in study design,data collection and analysis,decision to publish or preparation of the manuscript.We thank the Institutional Animal Care and Use Committee Animal Resources Center,and Animal Research Center.We also thank Z.R,Y.L.,C.M.,E.H.and B.Moon for providing experiment materials and helpful discussions.
文摘Dear Editor,CLDN18.2(CLDN),a member of tight junction protein family,is strictly limited to express on differentiated epithelial cells of the gastric mucosa and abnormal overexpression has been found in many cancers,especially in digestive system malignancies.1 Those features make CLDN a potential therapeutic target.However,monoclonal antibody targeting CLDN induce limited antitumor immune responses in clinical trials and fusion of strong immunomodulators might be needed to enhance its efficacy.High dose IL-2 activates tumor infiltrating lymphocytes(TILs),but the severe toxicity and poor tumor targeting limits its use.
